<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1">
  <stage>Registered</stage>
  <submitdate>6/07/2005</submitdate>
  <approvaldate>7/07/2005</approvaldate>
  <actrnumber>ACTRN12605000001695</actrnumber>
  <trial_identification>
    <studytitle>A phase II trial of gemcitabine in a fixed dose rate infusion combined with cisplatin in patients with operable biliary tract carcinomas</studytitle>
    <scientifictitle>A phase II trial of gemcitabine in a fixed dose rate infusion combined with cisplatin in patients with operable biliary tract carcinomas with the primary objective tumour response</scientifictitle>
    <utrn />
    <trialacronym>ABC trial</trialacronym>
    <secondaryid>National Clinical Trials Registry: NCTR570</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Adenocarcinoma of the gallbladder or intra/extrahepatic bile ducts</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Biliary tree (gall bladder and bile duct)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Gemcitabine delivered as fixed dose-rate infusion with cisplatin</interventions>
    <comparator>Single arm trial</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Objective tumour response.</outcome>
      <timepoint>Measured every 6 weeks during study treatment, and post treatment.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Tolerability and safety of treatment</outcome>
      <timepoint>Prior to each cycle of treatment, and at end of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of response</outcome>
      <timepoint>Prior to starting every second treatment cycle, then 6 monthly for 12 months, then as clinically indicated</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to treatment failure</outcome>
      <timepoint>Assessed at end of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to disease progression</outcome>
      <timepoint>Prior to starting every second treatment cycle, then 6 monthly for 12 months, then as clinically indicated</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Response rate using CA19-9</outcome>
      <timepoint>Before every treatment cycle, then 6 weekly until disease progression or 12 months, whicever occurs first</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival</outcome>
      <timepoint>6 weekly until death</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Histologic or cytologic diagnosis of adenocarcinogen of the gallbladder or intra/extrahepatic bile ducts with locally advanced or metastatic disease that is not amenable to curative surgical resection or with recurrent disease after prior surgical resection or radiotherapy. Measurable disease.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>No exclusion criteria</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/02/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>45</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC,QLD,SA,WA,TAS</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>AGITG/ NHMRC Clinical Trials Centre</primarysponsorname>
    <primarysponsoraddress>92-94 Parramatta Rd, Camperdown NSW 2050</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Eli Lilly Australia</fundingname>
      <fundingaddress>112 Wharf Rd, West Ryde, NSW 2114</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Prince of Wales Hospital Border Medical Oncology</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Austin Health</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St Vincent's Hospital- Melbourne</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Newcastle Mater Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Nepean Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Associate Professor David Goldstein</name>
      <address>Prince of Wales Hospital
High Street
Randwick NSW 2031</address>
      <phone>+61 2 93822577</phone>
      <fax />
      <email>GoldsteinD@SESAHS.NSW.GOV.AU</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Burcu Cakir</name>
      <address>NHMRC Clinical Trials Centre
Locked Bag 88
Camperdown NSW 2050</address>
      <phone>+61 2 95625000</phone>
      <fax>+61 2 95651863</fax>
      <email>GoldsteinD@SESAHS.NSW.GOV.AU</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>